Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Leo Pharma
Biotech
Leo's eczema prospect hits primary endpoint in phase 2b
Leo shared phase 2b data on temtokibart, reporting that the top three doses of the IL-22RA1 blocker beat placebo on the primary endpoint.
Nick Paul Taylor
May 9, 2025 7:30am
Gilead roars into JPM25 with $250M upfront deal for Leo
Jan 11, 2025 5:30pm
BenevolentAI names ex-Bayer R&D chief as new CEO
Jan 24, 2024 10:20am
Pfizer snags Roche early R&D head Pao—Chutes & Ladders
Feb 4, 2022 9:30am
Leo Pharma's new CEO comes from failed meme stock Orphazyme
Jan 31, 2022 12:09pm
Leo Pharma inks digital clinical trials partnership with Veeva
Sep 29, 2021 8:00am
